Search Results - Dapagliflozin

Explore the Latest #NephTrials Discussion on Dapagliflozin and CKD on the ISN’s Twitter Feed

The latest #NephTrials online discussion took place on March 10. Access the Twitter thread here. Twitter attendees joined Ron Gansevoort, Roberto Pecoits-Filho, Joel Topf, Manasi Bapat, and Swapnil Hiremath to discuss the RENAL LIFECYCLE trial. The conversation examined the composite and secondary outcomes of a randomized control trial investigating the effects of dapagliflozin on people with severe...

Join the ISN and Guests Live on March 10 for the Latest #NephTrials Discussion on the RENAL LIFECYCLE Trial Outcomes on Dapagliflozin and CKD

The next #NephTrials will be held on March 10, 2023, at 3 p.m. CET! Join Ron Gansevoort, primary investigator of the RENAL LIFECYCLE trial, in conversation with Michael Walsh, Roberto Pecoits-Filho, Joel Topf, Manasi Bapat, and Swapnil Hiremath. The panel will examine the composite and secondary outcomes of a randomized control trial investigating the effects...

Discover the Latest on DAPA-CKD: Dapagliflozin in Patients with Chronic Kidney Disease

The full DAPA-CKD trial results will be presented and reviewed at the ESC Congress 2020, Sunday, August 30, 17:00 – 17:30 CET. Topic Renal failure and Cardiovascular Disease Chairpersons Rory Collins (Oxford, UK); Frank Ruschitzka (Zurich, Switzerland) Presentations: DAPA-CKD – Dapagliflozin in Patients with CKD: Hiddo Heerspink (Groningen, Netherlands) DAPA- CKD – Live Prime Discussion: Diederick E Grobbee (Utrecht, Netherlands) Q&A Session The...

Optimization of SGLT2i Therapy Toolkit

             The toolkit on the optimization of SGLT2i therapy is the next output of a multi-society cardio-kidney-metabolic initiative, led by the ISN, to co-create toolkits for advancing the prevention and management of cardio-kidney complications. The toolkit consists of focused and practical infographics, serving as hands-on references for nephrologists, cardiologists and other healthcare professionals involved...

Global Trials Focus

The ISN-ACT (Advancing Clinical Trials) team presents this monthly round up of randomized trials in nephrology. Trials are selected not just for impact, but also to showcase the diversity of research produced by the global nephrology community. Each trial is reviewed in context and has a risk of bias assessment. We hope to drive...

ISN-SAN Webinar: Abordaje Integral del Síndrome Cardiorenometabólico: Fisiopatología y Manejo Clínico

Este webinario ofrece una visión completa del síndrome cardiorenometabólico (CRM), abordando su fisiopatología y estrategias de manejo. Se explorarán los mecanismos que vinculan corazón, riñones y metabolismo, junto con enfoques prácticos basados en las últimas evidencias para mejorar los resultados clínicos.La correcta comprensión del CRM es crucial para manejar la creciente pandemia no transmisible,...

Global Trials Focus

The ISN-ACT (Advancing Clinical Trials) team presents this monthly round up of randomized trials in nephrology. Trials are selected not just for impact, but also to showcase the diversity of research produced by the global nephrology community. Each trial is reviewed in context and has a risk of bias assessment. We hope to drive...

Trending Topics

Discover below the most-downloaded* articles at Kidney International® and Kidney International Reports® in the last few weeks. Full-text downloads are combined from the JBS dedicated journal platform and ScienceDirect platform Trending this week LAST UPDATED: March 14, 2025 TRAIL induces podocyte PANoptosis via death receptor 5 in diabetic kidney disease Effects of dialysate potassium concentration of 3.0 mmol/l with sodium zirconium...

eDIGEST: ISN Journals

Jan 2023 Edition Impact Factor 2022 19.6Kidney International 5.5Kidney International Supplements 6.0Kidney International Reports Recent publications in Kidney International Reports discuss the roles of glucose, blood pressure, and cardiovascular complications in chronic kidney disease.   Over the past three months, Kidney International has published several studies on the specific effects of SGLT2 inhibitors, lipotoxicity, genetics, endothelial stress responses,...

Global Trials Focus

The ISN-ACT (Advancing Clinical Trials) team presents this monthly round up of randomized trials in nephrology. Trials are selected not just for impact, but also to showcase the diversity of research produced by the global nephrology community. Each trial is reviewed in context and has a risk of bias assessment. We hope to drive...

Global Trials Focus

The ISN-ACT (Advancing Clinical Trials) team presents this monthly round up of randomized trials in nephrology. Trials are selected not just for impact, but also to showcase the diversity of research produced by the global nephrology community. Each trial is reviewed in context and has a risk of bias assessment. We hope to drive...

Global Trials Focus

The ISN-ACT (Advancing Clinical Trials) team presents this monthly round up of randomized trials in nephrology. Trials are selected not just for impact, but also to showcase the diversity of research produced by the global nephrology community. Each trial is reviewed in context and has a risk of bias assessment. We hope to drive...

ISN Webinar: Diabetes and its cardiac outcomes in people with and without kidney disease (CV outcome trials)

REGISTRATION ISN Webinar: Diabetes and its cardiac outcomes in people with and without kidney disease (CV outcome trials) Kidney failure and cardiovascular complications are critical complications in diabetic patients. Further, kidney disease is a significant risk for cardiovascular events independently of classical risk factors, which is called cardiorenal connection.  Recent large-scale cardiovascular outcome studies such as...

Global Trials Focus

Every month the ISN-ACT Team lists interesting new randomized controlled trials (RCTs) from around the world. Highlight: SGLT-2 inhibition strikes again Dapagliflozin in Patients with Chronic Kidney Disease See the latest trials here. A summary of the highlighted trial is now available in French, Mandarin, and Spanish. Support equal access to nephrology research: Become an ISN Member!

Breakthrough Discoveries

In celebration of the 60th Anniversary of the ISN, the ISN Research Working Group (RWG), under the leadership of Chair, Adeera Levin, and Deputy Chair, Masaomi Nangaku, publishes a monthly series, “Breakthrough Discoveries”. This series highlights 60 + 1 historical discoveries of significant impact to the nephrology community. So that the selection of discoveries was...